Skip to content

Sidra Iqbal

4 papers in the library · 542 citations · publishing 2013-2023

Papers

Sort Most recent Most cited

Ketamine versus ECT for Nonpsychotic Treatment-Resistant Major Depression.

New England Journal of Medicine May 24, 2023 A. Anand, S. Mathew, Gerard Sanacora et al. 263 citations

BACKGROUND Electroconvulsive therapy (ECT) and subanesthetic intravenous ketamine are both currently used for treatment-resistant major depression, but the comparative effectiveness of the two treatments remains uncertain. METHODS We conducted an open-label, randomized, noninferiority trial involving patients referred to ECT clinics for treatment-resistant major depression. Patients with...

Neural complexity EEG biomarkers of rapid and post-rapid ketamine effects in late-life treatment-resistant depression: a randomized control trial

Neuropsychopharmacology April 19, 2023 N. Murphy, Amanda J. F. Tamman, Marijn Lijffijt et al. 18 citations

Ketamine is an effective intervention for treatment-resistant depression (TRD), including late-in-life (LL-TRD). The proposed mechanism of antidepressant effects of ketamine is a glutamatergic surge, which can be measured by electroencephalogram (EEG) gamma oscillations. Yet, non-linear EEG biomarkers of ketamine effects such as neural complexity are needed to capture broader systemic effects,...

Bayesian adaptive randomization trial of intravenous ketamine for veterans with late-life, treatment-resistant depression.

Contemporary clinical trials communications December 1, 2019 Brittany O'Brien, Charles E. Green, Rayan K. Al Jurdi et al. 10 citations

More than eleven million U.S. Veterans are at least 65 years of age, an age group of which almost 20% suffers from clinically significant depressive symptoms. Available pharmacological treatments are suboptimal for patients, including veterans, with late-life depression. Ketamine has emerged as a potentially promising rapid-acting therapy for treatment-resistant depression (TRD). However, few...

Plasma brain derived neurotrophic factor (BDNF) and response to ketamine in treatment-resistant depression

The International Journal of Neuropsychopharmacology October 8, 2013 Colin N. Haile, James W. Murrough, Dan V. Iosifescu et al. 251 citations

Ketamine produces rapid antidepressant effects in treatment-resistant depression (TRD), but the magnitude of response varies considerably between individual patients. Brain-derived neurotrophic factor (BDNF) has been investigated as a biomarker of treatment response in depression and has been implicated in the mechanism of action of ketamine. We evaluated plasma BDNF and associations with...